IP Library Granted Patent US 10,604,753
Granted Patent B2
US 10,604,753 · App. 15/797,927 · Granted Mar 31, 2020

Focused libraries of genetic packages

Inventor: Robert Charles Ladner (Ijamsville, MD)
Assignee: Dyax Corp.
C12N15/1037C07K16/00C07K16/005C40B40/02C07K2317/565C40B40/08C40B40/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,604,753
App. No.
15/797,927
Granted
Mar 31, 2020
Kind
B2
Abstract

Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.

Claims (46)

1. An antibody library comprising a first set of variegated DNA molecules encoding a first collection of antibody light chains (LC), wherein each light chain comprises an LC CDR1 region, an LC CDR2 region, and an LC CDR3 region, and wherein:

(a) the first collection of antibody light chains are kappa light chains, which comprise a plurality of LC κ CDR3 regions selected from the group consisting of:

(1) QQ<3><1><1><1>P<1>T (SEQ ID NO:16), wherein <1> is a mixture of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y; and <3> is a mixture of amino acid residues Y, A, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, and W;

(2) QQ<3><3><1><1><1>P (SEQ ID NO:103), wherein <1> and <3> are as defined in (1) above;

(3) QQ<3><2><1><1>PP<1>T (SEQ ID NO:17), wherein <1> and <3> are as defined in (1) above and <2> is a mixture of amino acid residues S, A, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, and Y; and

(4) a mixture of any of (1) to (3) set forth above; or

(b) the first collection of antibody light chains are lambda light chains, which comprise a plurality of LC λ CDR3 regions selected from the group consisting of:

(1) <4><5><4><2><4>S<4><4><4><4>V (SEQ ID NO:106), wherein <2> is a mixture of amino acid residues D, N, A, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, and Y; <4> is a mixture of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, and W; and <5> is a mixture of amino acid residues S, A, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, and Y;

(2) <5>SY<1><5>S<5><1><4>V (SEQ ID NO:19), wherein <1> is a mixture of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and <4> and <5> are as defined in (1) above; and

(3) a mixture of (1) and (2) set forth above.

2. The library of claim 1 , wherein the first collection of antibody light chains are kappa light chains, which further comprises:

(A) a plurality of LC κ CDR1 regions selected from the group consisting of:

(1) RASQ<1>V<2><2><3>LA (SEQ ID NO:14), wherein <1> is a mixture of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <2> is a mixture of amino acid residues S, A, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, Y; and <3> is a mixture of amino acid residues Y, A, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W and S; and

(2) RASQ<1>V<2><2><2><3>LA (SEQ ID NO:15); wherein <1>, <2>, and <3> are as defined in (1) above; and

(3) a mixture of (1) and (2) set forth above;

(B) a plurality of LC κ CDR2 regions <1>AS<2>R<4><1> (SEQ ID NO:102), wherein <1> is a mixture of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <2> is a mixture of amino acid residues S, A, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, and Y; and <4> is a mixture of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; or

both (A) and (B).

3. The library of claim 1 , wherein the LC κ CDR3s (1), (2) and (3) are present in the library in a ratio of 0.65:0.1:0.25.

4. The library of claim 2 , wherein the LC κ CDR1s (1) and (2) are present in the library in a ratio of 0.68:0.32.

5. The library of claim 4 , wherein the first collection of antibody light chains are kappa light chains, and wherein the library further comprises a second set of variegated DNA molecules encoding a second collection of antibody light chains, which are lambda light chains comprising a plurality of LC λ CDR3 regions selected from the group consisting of:

(1) <4><5><4><2><4>S<4><4><4><4>V (SEQ ID NO:106), wherein <2> is a mixture of amino acid residues D, N, A, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, and Y; <4> is a mixture of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, and W; and <5> is a mixture of amino acid residues S, A, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W, and Y;

(2) <5>SY<1><5>S<5><1><4>V (SEQ ID NO:19), wherein <1> is a mixture of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and <4> and <5> are as defined in (1) above; and

(3) a mixture of (1) and (2) set forth above.

6. The library of claim 5 , wherein the second collection of antibody light chains further comprises:

(A) a plurality of LC λ CDR1 regions selected from the group consisting of:

(1) TG<1>SS<2>VG<1><3><2><3>VS (SEQ ID NO:18), wherein <1> is a mixture of amino acid residues T, G, A, D, E, F, H, I, K, L, M, N, P, Q, R, S, V, W, and Y, <2> is a mixture of amino acid residues D, N, A, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, and Y, and <3> is a mixture of amino acid residues Y, A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, and W;

(2) G<2><4>L<4><4><4><3><4><4>(SEQ ID NO:104), wherein <2> is as defined in (1) above, <3> is a mixture of amino acid residues Y, A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and <4> is a mixture of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and

(3) a mixture of (1) and (2) set forth above;

(B) a plurality of LCλ CDR2 regions <4><4><4><2>RPS (SEQ ID NO:105), wherein <2> is a mixture of amino acid residues D, N, A, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, and Y, and <4> is a mixture of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, and W; or

both (A) and (B).

7. The library of claim 6 , wherein the LC λ CDR3s (1) and (2) are present in the library in an equimolar mixture.

8. The library of claim 6 , wherein the LC λ CDR1s (1) and (2) are present in the library in a ratio of 0.67:0.33.

9. The library of claim 1 , wherein the first collection of antibody light chains are lambda chains, which further comprise

(A) a plurality of LC λ CDR1 regions selected from the group consisting of:

(1) TG<1>SS<2>VG<1><3><2><3>VS (SEQ ID NO:18), wherein <1> is a mixture of amino acid residues T, G, A, D, E, F, H, I, K, L, M, N, P, Q, R, S, V, W, and Y, <2> is a mixture of amino acid residues D, N and, A, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, and Y, and <3> is a mixture of amino acid residues Y, A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, and W;

(2) G<2><4>L<4><4><4><3><4><4>(SEQ ID NO:104), wherein <2> is as defined in (1) above, <3> is a mixture of amino acid residues Y, A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and <4> is a mixture of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and

(3) a mixture of (1) and (2) set forth above;

(B) a plurality of LC λ CDR2 regions <4><4><4><2>RPS (SEQ ID NO:105), wherein <2> is a mixture of amino acid residues D, N, A, E, F, G, H, I, K, L, M, P, Q, R, S, T, V, W, and Y and <4> is a mixture of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, and W; or

both (A) and (B).

10. The library of claim 9 , wherein the LC λ CDR3s (1) and (2) are present in the library in an equimolar mixture.

11. The library of claim 9 , wherein the LC λ CDR1s (1) and (2) are present in the library in a ratio of 0.67:0.33.

12. The library of claim 1 , wherein the library is a library of vectors.

13. The library of claim 12 , wherein the vectors are yeast vectors or phagemids.

14. The library of claim 1 , wherein the library is a library of genetic packages.

15. The library of claim 14 , wherein the genetic packages are cells, spores, or viral particles.

16. The library of claim 15 , wherein the genetic packages are phage particles or yeast cells, which display the collection of antibody light chains encoded by the variegated DNA molecules in the library.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2018
From: LADNER, ROBERT C.
To: DYAX CORP.
Reel/Frame 047521/0605 →
Continuity (7)
Continuation 13571661 · Aug 10, 2012
Continuation 13250520 · Sep 30, 2011
Continuation 12762051 · Apr 16, 2010
Continuation 11416460 · May 1, 2006
Continuation 10026925 · Dec 18, 2001
Provisional Application 60256380 · Dec 18, 2000
Related Publication 20180291368A1 · Oct 11, 2018